Revolutionizing Lung Cancer Care: Reveal-Dx Secures $4.2 Million in Funding

We are thrilled to announce that Reveal-Dx, a Seattle-based software company dedicated to transforming lung cancer outcomes, has successfully raised $4,200,000 in its latest funding round.

Founded in early 2021, Reveal-Dx is on a mission to deliver cutting-edge, AI-enabled radiomics decision support software, designed to enhance the clinical pathway for lung cancer patients.

This funding marks a significant milestone for our team, especially following our strategic acquisition of the assets from Mindshare Medical in March.

Mindshare Medical had invested millions and over five years of rigorous research into developing core, patented algorithms that are already being implemented in clinical settings for validation.

With this new capital, Reveal-Dx is poised to accelerate our product development and broaden our market reach, ensuring that our innovative solutions are accessible to healthcare providers and patients alike.

Our software harnesses advanced analytics to provide personalized treatment recommendations, ultimately driving improved patient outcomes and empowering clinicians with the vital information they need at critical decision points.

The support from our investors not only reaffirms the trust in our mission but will also enable us to enhance our technological capabilities and expand our team of experts.

As we continue our journey to redefine lung cancer care, we are excited about the positive impact our advancements will bring to patients battling this challenging disease.